These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

378 related items for PubMed ID: 19845257

  • 21. Circulating angiopoietin-2 is elevated in patients with neuroendocrine tumours and correlates with disease burden and prognosis.
    Srirajaskanthan R, Dancey G, Hackshaw A, Luong T, Caplin ME, Meyer T.
    Endocr Relat Cancer; 2009 Sep; 16(3):967-76. PubMed ID: 19502452
    [Abstract] [Full Text] [Related]

  • 22. A prospective evaluation of the effect of chronic proton pump inhibitor use on plasma biomarker levels in humans.
    Raines D, Chester M, Diebold AE, Mamikunian P, Anthony CT, Mamikunian G, Woltering EA.
    Pancreas; 2012 May; 41(4):508-11. PubMed ID: 22460728
    [Abstract] [Full Text] [Related]

  • 23. Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues.
    Nikou GC, Lygidakis NJ, Toubanakis C, Pavlatos S, Tseleni-Balafouta S, Giannatou E, Mallas E, Safioleas M.
    Hepatogastroenterology; 2005 May; 52(63):731-41. PubMed ID: 15966194
    [Abstract] [Full Text] [Related]

  • 24. Chromogranin A is a reliable biomarker for gastroenteropancreatic neuroendocrine tumors in an Asian population of patients.
    Chou WC, Hung YS, Hsu JT, Chen JS, Lu CH, Hwang TL, Rau KM, Yeh KY, Chen TC, Sun CF.
    Neuroendocrinology; 2012 May; 95(4):344-50. PubMed ID: 22343505
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Standard pre- and postoperative determination of chromogranin a in resectable non-functioning pancreatic neuroendocrine tumors--diagnostic accuracy: NF-pNET and low tumor burden.
    Jilesen AP, Busch OR, van Gulik TM, Gouma DJ, Nieveen van Dijkum EJ.
    Dig Surg; 2014 May; 31(6):407-14. PubMed ID: 25572908
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Biomarkers and molecular imaging in gastroenteropancreatic neuroendocrine tumors.
    Lindholm DP, Oberg K.
    Horm Metab Res; 2011 Nov; 43(12):832-7. PubMed ID: 22009449
    [Abstract] [Full Text] [Related]

  • 31. Prospective study of the value of serum chromogranin A or serum gastrin levels in the assessment of the presence, extent, or growth of gastrinomas.
    Goebel SU, Serrano J, Yu F, Gibril F, Venzon DJ, Jensen RT.
    Cancer; 1999 Apr 01; 85(7):1470-83. PubMed ID: 10193936
    [Abstract] [Full Text] [Related]

  • 32. Serum pancreastatin: the next predictive neuroendocrine tumor marker.
    Rustagi S, Warner RR, Divino CM.
    J Surg Oncol; 2013 Aug 01; 108(2):126-8. PubMed ID: 23775817
    [Abstract] [Full Text] [Related]

  • 33. Elevated chromogranin A (CgA) serum levels in the patients with advanced pancreatic cancer.
    Malaguarnera M, Cristaldi E, Cammalleri L, Colonna V, Lipari H, Capici A, Cavallaro A, Beretta M, Alessandria I, Luca S, Motta M.
    Arch Gerontol Geriatr; 2009 Aug 01; 48(2):213-7. PubMed ID: 18329114
    [Abstract] [Full Text] [Related]

  • 34. The biological characteristics of chromogranin A and its role as a circulating marker in neuroendocrine tumours.
    Ferrari L, Seregni E, Bajetta E, Martinetti A, Bombardieri E.
    Anticancer Res; 1999 Aug 01; 19(4C):3415-27. PubMed ID: 10629629
    [Abstract] [Full Text] [Related]

  • 35. NET Blood Transcript Analysis Defines the Crossing of the Clinical Rubicon: When Stable Disease Becomes Progressive.
    Pavel M, Jann H, Prasad V, Drozdov I, Modlin IM, Kidd M.
    Neuroendocrinology; 2017 Aug 01; 104(2):170-182. PubMed ID: 27078712
    [Abstract] [Full Text] [Related]

  • 36. Diagnostic value of tumor M2-pyruvate kinase in neuroendocrine tumors. A comparative study with chromogranin A.
    Pezzilli R, Migliori M, Morselli-Labate AM, Campana D, Ventrucci M, Tomassetti P, Corinaldesi R.
    Anticancer Res; 2003 Aug 01; 23(3C):2969-72. PubMed ID: 12926146
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Limitations of Chromogranin A in clinical practice.
    Marotta V, Nuzzo V, Ferrara T, Zuccoli A, Masone M, Nocerino L, Del Prete M, Marciello F, Ramundo V, Lombardi G, Vitale M, Colao A, Faggiano A.
    Biomarkers; 2012 Mar 01; 17(2):186-91. PubMed ID: 22303881
    [Abstract] [Full Text] [Related]

  • 39. Plasma chromogranin A levels predict survival and tumor response in patients with advanced gastroenteropancreatic neuroendocrine tumors.
    Chou WC, Chen JS, Hung YS, Hsu JT, Chen TC, Sun CF, Lu CH, Hwang TL.
    Anticancer Res; 2014 Oct 01; 34(10):5661-9. PubMed ID: 25275071
    [Abstract] [Full Text] [Related]

  • 40. The role of chromogranin A in the management of patients with phaeochromocytoma.
    Grossrubatscher E, Dalino P, Vignati F, Gambacorta M, Pugliese R, Boniardi M, Rossetti O, Marocchi A, Bertuzzi M, Loli P.
    Clin Endocrinol (Oxf); 2006 Sep 01; 65(3):287-93. PubMed ID: 16918946
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.